2024
Pre-operative stereotactic radiosurgery and peri-operative dexamethasone for resectable brain metastases: a two-arm pilot study evaluating clinical outcomes and immunological correlates
Jansen C, Pagadala M, Cardenas M, Prabhu R, Goyal S, Zhou C, Chappa P, Vo B, Ye C, Hopkins B, Zhong J, Klie A, Daniels T, Admassu M, Green I, Pfister N, Neill S, Switchenko J, Prokhnevska N, Hoang K, Torres M, Logan S, Olson J, Nduom E, del Balzo L, Patel K, Burri S, Asher A, Wilkinson S, Lake R, Kesarwala A, Higgins K, Patel P, Dhere V, Sowalsky A, Carter H, Khan M, Kissick H, Buchwald Z. Pre-operative stereotactic radiosurgery and peri-operative dexamethasone for resectable brain metastases: a two-arm pilot study evaluating clinical outcomes and immunological correlates. Nature Communications 2024, 15: 8854. PMID: 39402027, PMCID: PMC11473782, DOI: 10.1038/s41467-024-53034-6.Peer-Reviewed Original ResearchConceptsPre-operative stereotactic radiosurgeryCD8 T cellsEffector-like cellsT cellsStereotactic radiosurgeryBrain metastasesCD8 T cell responsesEndpoint of overall survivalDistant brain failureResected brain metastasesEfficacy of immunotherapyT cell responsesAntigen presenting cellsSecondary clinical endpointsLocal recurrenceLeptomeningeal diseaseOverall survivalImmune compositionProspective trialsImmune nichePrimary endpointImmunological correlatesPresenting cellsClinical outcomesPilot studyUnderstanding and overcoming resistance to immunotherapy in genitourinary cancers
Evans S, Jani Y, Jansen C, Yildirim A, Kalemoglu E, Bilen M. Understanding and overcoming resistance to immunotherapy in genitourinary cancers. Cancer Biology & Therapy 2024, 25: 2342599. PMID: 38629578, PMCID: PMC11028033, DOI: 10.1080/15384047.2024.2342599.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsResistance to immunotherapyImmunotherapy resistanceTargeted therapyGenitourinary (GU) cancersCombined immune checkpoint inhibitorsIntroduction of novel immunotherapiesMechanisms of immunotherapy resistanceOvercome resistance to immunotherapyCancer cellsHost immune profileResponse to immunotherapyNovel targeted therapiesImmune system's rolePredictors of responseAttack cancer cellsImmune system's abilityStandard of careCheckpoint inhibitorsSequential therapyNovel immunotherapiesCombination therapyTreatment failureGU cancersTreatment landscapeImpact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis
Patel J, Woo Y, Draper A, Jansen C, Carlisle J, Innominato P, Lévi F, Dhabaan L, Master V, Bilen M, Khan M, Lowe M, Kissick H, Buchwald Z, Qian D. Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis. Journal For ImmunoTherapy Of Cancer 2024, 12: e008011. PMID: 38531662, PMCID: PMC10966813, DOI: 10.1136/jitc-2023-008011.Peer-Reviewed Original ResearchConceptsInfusions of immune checkpoint inhibitorsMetastatic renal cell carcinomaProgression-free survivalOverall survivalRenal cell carcinomaCell carcinomaInternational Metastatic RCC Database Consortium risk scoreAssociated with longer progression-free survivalLung cancerGroup BGroup ATime of ICI initiationLonger progression-free survivalNon-small cell lung cancerMultivariable Cox proportional hazards regressionImmune checkpoint inhibitorsPretreatment lactate dehydrogenaseCell lung cancerCox proportional hazards regressionAdaptive immune responsesProportional hazards regressionMulticenter cohort analysisCheckpoint inhibitorsICI initiationMetastatic melanomaHow to diversify the dwindling physician–scientist workforce after the US affirmative action ban
Ding J, Christophers B, Rupert D, Tang C, Serafini R, Jansen C, Curtis M, Chesebro A, Waldman A. How to diversify the dwindling physician–scientist workforce after the US affirmative action ban. Nature Medicine 2024, 30: 635-637. PMID: 38291299, DOI: 10.1038/s41591-023-02787-6.Peer-Reviewed Original ResearchEstablished and Emerging Biomarkers of Immunotherapy in Renal Cell Carcinoma
Jani Y, Jansen C, Gerke M, Bilen M. Established and Emerging Biomarkers of Immunotherapy in Renal Cell Carcinoma. Immunotherapy 2024, 16: 405-426. PMID: 38264827, DOI: 10.2217/imt-2023-0267.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaCell carcinomaImmune checkpoint inhibitorsBiomarker of immunotherapyRisk of adverse eventsSignificant side effectsCheckpoint inhibitorsDevelopment of biomarkersAdverse eventsImmunotherapyTherapeutic efficacySide effectsPatientsClinical biomarkersPatient's diseaseTherapeutic biomarkersClinician's abilityBiomarkersCarcinomaPatient careImproving clinicians' abilityEfficacy
2023
Cutaneous T-cell lymphoma with CNS involvement: a case series and review of the literature
Preston J, Jansen C, Kosaraju S, Niyogusaba T, Zhuang T, Iwamoto S, Hutto S, Lechowicz M, Allen P. Cutaneous T-cell lymphoma with CNS involvement: a case series and review of the literature. CNS Oncology 2023, 12: cns105. PMID: 37877303, PMCID: PMC10701703, DOI: 10.2217/cns-2023-0014.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaCentral nervous systemCNS metastasesCases of cutaneous T-cell lymphomaDevelopment of CNS metastasesCentral nervous system involvementRare hematologic malignancyCNS-directed therapyDegree of remissionHematologic malignanciesProgressive diseaseMedian timeCase seriesTreatment responseTherapeutic guidelinesPathological characteristicsCutaneous lesionsMetastasisNervous systemLymphomaPatientsSurvivalInvolvementRemissionPhysician–scientist trainees with parenting responsibilities need financial and childcare support
Jansen C, Sugiura A, Stalbow L, Nguyen C, Lever J, Peiper A, Plaza-Jennings A, Varvel L, Williams M, Zarrinpar A, Swartz T. Physician–scientist trainees with parenting responsibilities need financial and childcare support. Nature Medicine 2023, 29: 2990-2992. PMID: 37853137, PMCID: PMC10842773, DOI: 10.1038/s41591-023-02606-y.Peer-Reviewed Original Research
2022
CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor
Prokhnevska N, Cardenas M, Valanparambil R, Sobierajska E, Barwick B, Jansen C, Reyes Moon A, Gregorova P, delBalzo L, Greenwald R, Bilen M, Alemozaffar M, Joshi S, Cimmino C, Larsen C, Master V, Sanda M, Kissick H. CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. Immunity 2022, 56: 107-124.e5. PMID: 36580918, PMCID: PMC10266440, DOI: 10.1016/j.immuni.2022.12.002.Peer-Reviewed Original ResearchConceptsTumor-draining lymph nodesCD8<sup>+</sup> T cell activationT cell activationCD8<sup>+</sup> T cellsStem-like cellsT cellsCell activationEffector differentiationLymph nodesTumor-specific CD8<sup>+</sup> T cellsActivated CD8<sup>+</sup> T cellsAnti-tumor T cell responsesTumor-draining lymph node cellsCD8+ T cell activationCo-stimulationT cell responsesAntigen-presenting cellsMurine tumor modelsResponse to cancerEffector phenotypeTumor immunotherapyTumor modelTumorCell responsesAcute virusesClinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood
Carlisle J, Jansen C, Cardenas M, Sobierajska E, Reyes A, Greenwald R, Del Balzo L, Prokhnevska N, Kucuk O, Carthon B, Mullane P, Osunkoya A, Baumgarten D, Hosseinzadeh F, Wilkinson S, Lake R, Sowalsky A, Liu Y, Master V, Bilen M, Kissick H. Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood. Journal For ImmunoTherapy Of Cancer 2022, 10: e004803. PMID: 35863822, PMCID: PMC9310235, DOI: 10.1136/jitc-2022-004803.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaCD8 T cellsCheckpoint therapyT cellsHLA-DRCell carcinomaClinical benefitActivation markers HLA-DRAdvanced renal cell carcinomaPre-existing immune responsesImmune responsePredictor of clinical benefitPeripheral T cell activationPeripheral blood of patientsFlow cytometryT-cell receptor (TCR) sequencingIntratumoral T cellsAntitumor immune responseMarkers HLA-DRAbundant T cellsProportion of CD4Cornerstone of treatmentT cell activationBlood of patientsPredicting therapeutic response
2021
A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes
Calagua C, Ficial M, Jansen C, Hirz T, Del Balzo L, Wilkinson S, Lake R, Ku A, Voznesensky O, Sykes D, Saylor P, Ye H, Signoretti S, Kissick H, Sowalsky A, Balk S, Einstein D. A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. Clinical Cancer Research 2021, 27: 4836-4847. PMID: 34168052, PMCID: PMC8416924, DOI: 10.1158/1078-0432.ccr-21-0121.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaCD8<sup>+</sup> T cellsImmune checkpoint inhibitorsPD-L1 expressionLocalized prostate cancerPrimary prostate cancerProstate cancerT cellsPD-L1Density of CD8<sup>+</sup> T cellsHigh-risk primary prostate cancerCD8 T-cell densityCharacterized tumor infiltrating lymphocytesLocalized prostate cancer casesPD-1<sup>+</sup> cellsTumor PD-L1 expressionUnique tumor immune microenvironmentPD-1 expressionTumor-infiltrating lymphocytesT-cell densityCD8 T cellsTumor immune microenvironmentTumor mutational burdenProstate cancer casesT-cell content
2020
Pandemic Pause: Lessons in Unscrambling My Daily Life
Jansen C. Pandemic Pause: Lessons in Unscrambling My Daily Life. Academic Medicine 2020, 95: 10.1097/acm.0000000000003635. PMID: 32739930, PMCID: PMC7409522, DOI: 10.1097/acm.0000000000003635.Peer-Reviewed Original ResearchConsiderations for cancer immunotherapy biomarker research during COVID-19
Carlisle J, Jansen C, Bilen M, Kissick H. Considerations for cancer immunotherapy biomarker research during COVID-19. Endocrine Related Cancer 2020, -1: c1-c8. PMID: 32508308, PMCID: PMC7385701, DOI: 10.1530/erc-20-0187.Peer-Reviewed Original ResearchThe immunosuppressive phenotype of tumor-infiltrating neutrophils is associated with obesity in kidney cancer patients
Margaroli C, Cardenas M, Jansen C, Reyes A, Hosseinzadeh F, Hong G, Zhang Y, Kissick H, Tirouvanziam R, Master V. The immunosuppressive phenotype of tumor-infiltrating neutrophils is associated with obesity in kidney cancer patients. OncoImmunology 2020, 9: 1747731. PMID: 32313729, PMCID: PMC7153842, DOI: 10.1080/2162402x.2020.1747731.Peer-Reviewed Original ResearchConceptsKidney cancer patientsTumor microenvironmentArginase-1Tumor tissuesActivated phenotypeCancer patientsMyeloid-derived suppressor cellsImmature-like phenotypeTumor-infiltrating neutrophilsTumor-associated neutrophilsEnzyme arginase-1Associated with obesityPhenotype of neutrophilsAdipose tissue distributionMetabolic statePatient's metabolic stateSuppressor cellsImmunosuppressive phenotypeImmunosuppressive roleTumor progressionTumor neutrophilsDisease progressionCirculating neutrophilsTumorGranule release
2019
An intra-tumoral niche maintains and differentiates stem-like CD8 T cells
Jansen C, Prokhnevska N, Master V, Sanda M, Carlisle J, Bilen M, Cardenas M, Wilkinson S, Lake R, Sowalsky A, Valanparambil R, Hudson W, McGuire D, Melnick K, Khan A, Kim K, Chang Y, Kim A, Filson C, Alemozaffar M, Osunkoya A, Mullane P, Ellis C, Akondy R, Im S, Kamphorst A, Reyes A, Liu Y, Kissick H. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature 2019, 576: 465-470. PMID: 31827286, PMCID: PMC7108171, DOI: 10.1038/s41586-019-1836-5.Peer-Reviewed Original ResearchConceptsCD8 T cellsStem-like CD8 T cellsT cellsStem-like T cellsCD8 T cell infiltrationCD8 T cell responsesMechanism of immune escapeTumor-infiltrating lymphocytesT cell infiltrationT cell responsesStem-like cellsSurvival benefitImmune nicheProgressive diseaseImmune escapeTumor typesTumorCD8Human cancersDifferentiation processLymphocytesPatientsCancerInfiltrationSurvival
2018
The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer
Jansen C, Prokhnevska N, Kissick H. The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer. Urologic Oncology Seminars And Original Investigations 2018, 37: 543-555. PMID: 30446449, PMCID: PMC6513714, DOI: 10.1016/j.urolonc.2018.10.011.Peer-Reviewed Original Research
2015
Role of the Gut Microbiota of Children in Diarrhea Due to the Protozoan Parasite Entamoeba histolytica
Gilchrist C, Petri S, Schneider B, Reichman D, Jiang N, Begum S, Watanabe K, Jansen C, Elliott K, Burgess S, Z. J, Alam M, Kabir M, Haque R, Petri W. Role of the Gut Microbiota of Children in Diarrhea Due to the Protozoan Parasite Entamoeba histolytica. The Journal Of Infectious Diseases 2015, 213: 1579-1585. PMID: 26712950, PMCID: PMC4837909, DOI: 10.1093/infdis/jiv772.Peer-Reviewed Original ResearchConceptsProtozoan parasite Entamoeba histolyticaParasite Entamoeba histolyticaModerate-to-severe diarrheaPediatric diarrheal diseaseAssociated with protectionAssociated with diarrheaE. histolytica infectionUrban slums of DhakaEtiological agent of amebiasisPopulation-based surveyNatural historyDiarrheaImmunoglobulin ADiarrheal diseaseEtiological agentSlums of DhakaGut microbiotaEstimated 1Sub-Saharan AfricaInfectionParasite burdenE. histolyticaUrban slumsChildrenInfants